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ABSTRACT
Introduction: Clinical guidelines generally
recommend endocrine therapy over
chemotherapy for hormone receptor-positive
advanced breast cancer (unless life-threatening
metastases are present). This study aimed to
assess the real-world treatment patterns of
patients with hormone receptor-positive
advanced breast cancer in Europe and the
United States.
Methods: Treatment patterns in Europe
(France, Germany, Italy, Spain, and the UK)
and the United States from January 2012 to
December 2014 were investigated using a
patient record database (Global Oncology
Monitor). Sample data were projected to the
wider clinical population to provide running
annual estimates every 3 months.
Results: Sample sizes ranged from 1272 to 1640
patients in Europe and from 2225 to 2760
patients in the United States. Across all lines
of therapy, 37–43% (Europe) and 45–50%
(United States) of patients received
chemotherapy. More patients received
endocrine therapy than chemotherapy as
first-line treatment for advanced breast cancer
(Europe: 51–54% vs. 33–35%; United States:
53–60% vs. 34–42%). In contrast, endocrine
therapy-only regimens were given less
commonly than chemotherapy-only regimens
in the third-line setting in both Europe and the
United States.
Conclusions: Chemotherapy is used
extensively in routine clinical practice for
hormone receptor-positive, human epidermal
growth factor receptor 2-negative advanced
breast cancer. The results also suggest that the
treatment patternsin Europe and the United
States are qualitatively different.
Funding: Ipsos Healthcare and AstraZeneca.
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INTRODUCTION
Clinical guidelines produced by the joint
European School of Oncology/European
Society of Medical Oncology task force and by
the National Comprehensive Cancer Network
recommend that patients with hormone
receptor (HR)-positive, human epidermal
growth factor receptor (HER)2-negative
advanced breast cancer should be treated with
endocrine therapy, including when
asymptomatic visceral metastases are present
[1, 2]. Cytotoxic chemotherapy has proven
efficacy but, due to its tolerability profile,
should be reserved for patients with rapidly
progressing disease and/or endocrine resistance
[1, 2]. Recommended endocrine therapies
include the selective estrogen receptor
modulator tamoxifen; third-generation
aromatase inhibitors (AIs) anastrozole,
letrozole, and exemestane; and the selective
estrogen receptor downregulator fulvestrant [3].
Limited data are available for assessing the
use of these treatments in routine practice. We
report real-world use of these therapies for the
treatment of postmenopausal patients with
HR-positive, HER2-negative advanced breast
cancer in Europe and the United States.
METHODS
Study Design and Participants
The Global Oncology Monitor (Ipsos
Healthcare, London, UK)—a large
physician-based syndicated patient record
database—was used to identify treatments
given to postmenopausal patients with
HR-positive, HER2-negative locally advanced/
metastatic breast cancer (stage IIIb/stage IV) in
five European countries (France, Germany,
Italy, Spain, and the UK) and the United
States. Annually, approximately 1300 oncology
physicians (representing over 105,000 patients)
continuously complete patient case histories for
approximately 5–30 patients currently receiving
treatment and seen by the physician in the
previous month. The majority of records were
collected online and the remainder via paper
forms. Responding physicians were the primary
decision-maker for included patients. The
Global Oncology Monitor is validated with
market sizing studies every 2 years to ensure
that the size and representativeness of the
physician sample reflects the wider population
of relevant treating physicians. This article is
based on previously conducted studies, and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
Patient records were reviewed for type and
duration of treatment. The evaluation period
ran from January 1, 2012, until December 31,
2014. Sample data based on annual market
sizing were projected to the wider clinical
population to provide running annual
estimates every 3 months. Projections were
adjusted for physician, practice type, line of
therapy, and cancer type and stage to reflect
clinical practice.
Projected treatments were allocated to the
following mutually exclusive categories:
chemotherapy only; ‘‘biologics’’ only
(including palbociclib, everolimus, and
trastuzumab); endocrine therapy only;
chemotherapy plus biologics; chemotherapy
plus endocrine therapy; and biologics plus
endocrine therapy. Subgroup analyses were
performed on the following groups of patients
receiving first-line treatment for locally
advanced/metastatic breast cancer: patients
receiving their first ever drug treatment for
breast cancer within the locally advanced/
metastatic setting, who had been diagnosed
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within the previous 3 months (‘‘no prior drug
treatment [diagnosis B3 months]’’); patients
receiving their first ever drug treatment for
breast cancer but who had been diagnosed more
than 3 months previously (‘‘no prior drug
treatment [diagnosis [3 months]’’); patients
who had previously received drug treatment
for early breast cancer and experienced disease
progression within B12 months of treatment
(‘‘early recurrence’’); and patients who had
received drug treatment for early breast cancer
and experienced disease progression [12
months after treatment (‘‘late recurrence’’; this
group also included patients whose time to
recurrence was unknown). Results for this
observational report are descriptive, with no
additional statistical analysis. Values are
reported as ranges of running annual estimates
unless otherwise stated.
RESULTS
The representative sample of physicians in the
United States comprised those in office or
private clinics (68%), universities or teaching
hospitals (17%), general hospitals (11%) and
comprehensive cancer centers (5%). In Europe,
physicians were at university or teaching
hospitals (45%), general hospitals (29%),
comprehensive cancer centers (18%) or office/
private clinics (7%). The sample sizes used every
3 months ranged from 1272 to 1640 patients in
Europe (France, Germany, Italy, Spain, and the
UK) and from 2225 to 2760 patients in the
United States (Table 1). All patients were being
treated with an anti-cancer drug at the time
their data was recorded. Among these, 45–66%
(Europe) and 37–53% (United States) of patients
were receiving their first line of anti-cancer drug
treatment for advanced disease during the
evaluation period; 22–42% (Europe) and
23–29% (United States) were receiving their
second-line treatment; and 12–17% (Europe)
and 22–39% (United States) were receiving
third- or later-line treatment.
When assessed across all lines of therapy,
running annual projections during the
evaluation period indicated that endocrine
therapy-only and chemotherapy-only regimens
were the most commonly prescribed
treatments, with each category accounting for
approximately 40% of projected treatments in
Europe (43–47% and 37–43%, respectively) and
the United States (39–42% and 45–50%,
respectively; Fig. 1). Chemotherapy plus
biologics and biologics plus endocrine therapy
were received by 6–8% and 1–9% of patients in
Europe, and 0–2% and 4–11% of patients in the
United States, respectively. Fewer than 4% of
patients received biologics only or
chemotherapy plus endocrine therapy in
either Europe or the United States.
In the first-line setting, endocrine
therapy-only regimens were given more
commonly than chemotherapy-only regimens
in Europe (51–54% vs. 33–35%) and the United
States (53–60% vs. 34–42%) during the
evaluation period (Fig. 1). In the third-line
setting, endocrine therapy-only regimens were
given less commonly than chemotherapy-only
regimens in both Europe and the United States.
There were no clear differences in patterns of
use between endocrine-only and
chemotherapy-only regimens in the
second-line setting.
Fig. 1 Projected treatment regimen use among patients
with hormone receptor-positive, human epidermal growth
factor receptor 2-negative locally advanced/metastatic
breast cancer in Europe and the United States by line of
therapy for advanced disease. Data taken from Ipsos
Healthcare Global Oncology Monitor, January
2012–December 2014 (see Table 1 for sample sizes). 
Ipsos, all rights reserved
c
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In Europe, when assessed by category,
first-line treatment patterns appeared similar
between chemotherapy-only and endocrine
therapy-only regimens in patients with
late-recurrent disease (Fig. 2). Patients in the
no-prior-drug-treatment (diagnosis B3 months)
and no-prior-drug-treatment (diagnosis[3
months) subgroups more commonly received
endocrine therapy-only than
chemotherapy-only regimens. In the
early-recurrence subgroup, the proportion of
patients who received endocrine therapy only
decreased over the evaluation period, reaching a
level similar to patients who received
chemotherapy-only regimens. However, there
was also an increase over this time in the
proportion of patients in the early-recurrence
subgroup who received endocrine therapy plus
biologics.
In the United States, fewer patients with no
prior drug treatment (diagnosis B3 months)
received first-line endocrine therapy-only
versus chemotherapy-only regimens (Fig. 2). A
higher proportion of patients received
endocrine therapy-only compared with
chemotherapy-only regimens in the
no-prior-drug-treatment (diagnosis
[3 months), early-recurrence, and
late-recurrence subgroups.
DISCUSSION
Data from this analysis of a patient record
database suggest that a substantial proportion
of patients with HR-positive, HER2-negative
advanced breast cancer receive chemotherapy.
A previous US database analysis from 2002 to
2012 observed similar values for the proportion
of patients receiving chemotherapy (40%) and
endocrine therapy (60%) for first-line treatment
of HR-positive, HER2-negative metastatic breast
cancer [4]. This study extends these
observations to Europe, and suggests that
these patterns have remained consistent in
subsequent years. Although the design and
scope of this study prevent any firm
conclusions from being drawn regarding
treatment use versus guideline
recommendations (and all treatment decisions
should be made on an individualized basis), it is
possible that some physicians could be better
educated on the benefits of endocrine therapy
compared with chemotherapy for HR-positive
advanced breast cancer. Use of endocrine
therapy in combination with biologics
appeared to increase during the evaluation
period. This may reflect the approval of
everolimus in 2012 by both the European
Medicines Agency [5] and the US Food and
Drug Administration [6] for use in combination
with exemestane in patients with HR-positive,
HER2-negative advanced breast cancer that has
progressed during prior treatment with AIs.
The data presented here suggest important
qualitative differences in first-line treatment of
HR-positive, HER2-negative advanced breast
cancer between the subgroups of patients
analyzed and between Europe and the United
States. For example, chemotherapy regimens
were used preferentially in the first-line setting
for advanced breast cancer in patients in the
United States with no prior drug treatment
(diagnosis B3 months). However, in Europe, a
greater proportion of patients were given
endocrine therapy than chemotherapy in this
setting. A previously published study has also
bFig. 2 Projected treatment regimen use among patients
receiving ﬁrst-line treatment for hormone receptor-posi-
tive, human epidermal growth factor receptor 2-negative
locally advanced/metastatic breast cancer in Europe and
the United States by category of advanced disease. Data
taken from Ipsos Healthcare Global Oncology Monitor,
January 2012–December 2014 (see Table 1 for sample
sizes).  Ipsos, all rights reserved
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found European practice patterns to be
generally consistent with guideline
recommendations [7]. However, to our
knowledge, there have been no published
studies that have investigated the differences
in practice patterns for advanced breast cancer
between the United States and Europe.
Therefore, initial study could prompt more
in-depth investigation.
It is possible that the apparent low
utilization of endocrine therapy for advanced
breast cancer, especially as second- and
third-line therapies, may be because patients
develop rapidly progressing disease after
first-line treatment (possibly also with the
presence of life-threatening visceral
metastases), making them candidates for
chemotherapy. Alternatively, physicians may
have reasons to expect further lines of
endocrine therapy to lack benefit due to the
development of endocrine resistance [8], or
they may be willing to concede the increased
toxicity with chemotherapy with an
expectation of achieving more effective disease
control [4]. This could be interpreted as a belief
by some physicians that the risk–benefit profile
of endocrine therapies in the second- and
third-line settings are not superior to
chemotherapy [4]. However, these speculations
extend beyond the current study, and the
relevant data regarding physicians’
motivations for therapy choice were not
collected.
These results should be interpreted with
caution and within the limitations of this
patient database analysis. No statistical
analyses were incorporated into this study,
which was intended to be descriptive.
Furthermore, data were not available within
the scope of the study to fully define the patient
population that may be eligible for
chemotherapy according to clinical guidelines
(i.e., with rapidly progressive disease or proven
endocrine resistance).
CONCLUSION
Based on the data presented, we conclude that
chemotherapy appears to be used extensively
for the treatment of hormone receptor-positive
advanced breast cancer in routine clinical
practice in Europe and the United States.
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